$1.28
4.07% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Erasca Inc Stock price

$1.28
+0.04 3.23% 1M
-1.36 51.52% 6M
-1.23 49.00% YTD
-0.96 42.86% 1Y
-4.50 77.85% 3Y
-16.15 92.66% 5Y
-16.15 92.66% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 4.07%
ISIN
US29479A1088
Symbol
ERAS
Sector
Industry

Key metrics

Market capitalization $362.61m
Enterprise Value $108.83m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.91
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-153.87m
Free Cash Flow (TTM) Free Cash Flow $-107.82m
Cash position $304.59m
EPS (TTM) EPS $-0.62
P/E forward negative
Short interest 8.75%
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Erasca Inc forecast:

Buy
100%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 3.60 3.60
6% 6%
-
-3.60 -3.60
6% 6%
-
- Selling and Administrative Expenses 34 34
10% 10%
-
- Research and Development Expense 113 113
8% 8%
-
-150 -150
8% 8%
-
- Depreciation and Amortization 3.60 3.60
6% 6%
-
EBIT (Operating Income) EBIT -154 -154
7% 7%
-
Net Profit -158 -158
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
7 days ago
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE...
Neutral
GlobeNewsWire
8 days ago
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasd...
Neutral
GlobeNewsWire
14 days ago
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Man...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 103
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today